Omron Healthcare Showcases Product at Japan Diabetes Society Annual
Meeting
WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that
develops wearable medical technology and point-of-care tests to help
patients and physicians manage chronic pain, nerve diseases, and sleep
disorders, today reported the marketing launch in Japan of NC-stat®
DPNCheck®. Omron Healthcare, the Company's exclusive
distributor for Japan and other key Asian markets, is leading the
launch. The Annual Meeting of the Japan Diabetes Society is the premier
diabetes event for Japanese healthcare professionals and is the venue
for initiating the DPNCheck product awareness campaign. The 57th
Annual Meeting of the Japan Diabetes Society is being held at the Osaka
International Convention Center during May 22 to 24, 2014.
NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care
test to detect diabetic peripheral neuropathy, or DPN, at an early stage
allowing physicians to select appropriate treatment. DPN is the most
common complication of diabetes, affecting over half of people with
diabetes. DPN causes significant morbidity including pain, increased
risk of falling in the elderly, and is the primary trigger for diabetic
foot ulcers which may require lower extremity amputations.
Diabetes is a major health issue in Japan affecting over 7 million
people or 7.6% of its adult population. Japan is also a unique market.
It has a combination of physician reimbursement for nerve conduction
testing and an approved pharmacological agent for treating diabetic
peripheral neuropathy. As the home market for Omron Healthcare, Omron
has a strong presence through complimentary products and broad,
established distribution. Omron is currently guiding DPNCheck through
the Japan regulatory process which is expected to conclude during this
quarter.
Luminaries at this year's Annual Meeting of the Japan Diabetes Society
include Andrew J.M. Boulton, M.R.C.P. (UK), M.D., F.R.C.P., Professor of
Medicine, University of Manchester and Consultant Physician, Manchester
Royal Infirmary, Manchester, UK, and Professor of Medicine, Diabetes
Research Institute, University of Miami; and Jiro Nakamura, M.D., Ph.D.,
Professor, Division of Diabetes, Department of Internal Medicine,
Diabetes Center at the Aichi Medical University School of Medicine,
Nagakute, Japan. Dr. Boulton and Dr. Nakamura both serve on the
NeuroMetrix Scientific Advisory Board. Professor Boulton will deliver a
keynote presentation on May 23rd at the Annual Meeting entitled
"Diagnosis and Management of Diabetic Neuropathy and its Endpoints".
Professor Nakamura will Chair several sessions at the Annual Meeting
including "The Imperceptible Advance of Neuropathy: from Peripheral
Nerve Disorder to Dysautonomia". DPNCheck will receive attention during
these scientific sessions and will figure prominently at the Omron
Healthcare booth at the Annual Meeting.
Product information is available at http://www.DPNCheck.com.
About Omron
Omron Healthcare, headquartered in Kyoto, Japan, is a global leader in
health care monitoring. The company offers a wide range of devices and
services that help prevent and manage lifestyle diseases such as blood
pressure monitors, body composition monitors and activity counters as
well as medical devices such as vascular screening devices and visceral
fat monitors in more than 100 countries. For more information on Omron
Healthcare, visit www.healthcare.omron.co.jp/english/.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The Company markets
the SENSUS™ device for treating chronic pain, focusing on
physicians managing patients with neuropathic pain such as painful
diabetic neuropathy. The Company also markets DPNCheck, which is a
rapid, accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
News Provided by Acquire Media
